Mounjaro success rate: what the clinical trial results actually show

What the SURMOUNT programme found, and why those numbers matter

The headline figures from SURMOUNT-1 are well-cited, but the detail is what makes them meaningful. Participants took tirzepatide for 72 weeks alongside a reduced-calorie diet and increased physical activity. At 5mg, average weight loss was around 15%; at 10mg, roughly 19.5%; at 15mg, around 20–21%. A proportion of participants lost considerably more. The placebo group lost an average of just under 3%, which tells you most of the effect is the medicine rather than the lifestyle support alone.

For context on how the tirzepatide success rate compares across the class, the 2025 SURMOUNT-5 head-to-head trial directly compared tirzepatide with semaglutide 2.4mg over 72 weeks in 751 adults with obesity. Tirzepatide produced the larger average reduction. That does not make semaglutide ineffective (Wegovy at 2.4mg still averaged around 15% in its own pivotal trial) but it gives prescribers a factual basis for the conversation about which medicine suits a particular patient.

NICE reviewed this evidence in detail before publishing its appraisal of tirzepatide (TA1026, updated September 2025), concluding that tirzepatide is cost-effective for NHS use at defined thresholds. That endorsement reflects the strength of the trial programme, thousands of participants, a consistent dose-response pattern, and rigorous methodology.

Why individual results differ from the trial averages

A trial average is a group statistic. Some participants in SURMOUNT-1 lost considerably more than 20%; others lost less. The factors that shift outcomes in real life are worth understanding before starting treatment.

Dose matters most. The 2.5mg starting dose exists to settle the digestive system during the adjustment period, it is not the dose that drives most of the weight loss seen in trials. Titration toward the highest tolerated dose, typically over several months, is where the clinical effect builds. Patients who cannot tolerate escalation still benefit, but tend to see smaller average losses than those who reach 15mg.

Adherence shapes results substantially. Participants in SURMOUNT-1 were closely supported. In routine clinical practice, missed doses, early discontinuation, and inconsistent lifestyle changes all reduce average outcomes. Our guide to weight loss on Mounjaro covers the practical factors (protein intake, hydration, staying active) that the trial participants had structured support for.

Biology also plays a role. Starting weight, metabolic history, hormonal factors, and whether someone has type 2 diabetes (which attenuates the weight effect somewhat, as seen in the SURPASS trials) all influence the individual response. A prescriber who knows your full picture can help set realistic expectations from the start.

What counts as success, and what the evidence says about stopping

NICE's guidance on tirzepatide includes a practical benchmark: if someone has not lost at least 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. That threshold is a clinical checkpoint, not a verdict. Some people lose more weight more slowly; others plateau and then resume losing.

The question of what happens after stopping is one our prescribers discuss regularly. The evidence around coming off Mounjaro suggests weight tends to return when the medicine is stopped, particularly without sustained lifestyle changes, a pattern consistent with obesity being a chronic condition rather than a short-term problem to solve. The NICE recommendation for tirzepatide does not impose the two-year cap that applies to semaglutide under TA875; continuation beyond two years is subject to ongoing clinical review.

For those weighing up cost alongside these outcomes, our overview of Mounjaro pricing in the UK explains what private treatment typically includes and why the prescription component matters as much as the price. Success rate figures only mean something if the supply chain is verified and the clinical oversight is real.

The private route for people who cannot access Mounjaro on the NHS yet

NICE recommended tirzepatide for NHS use in December 2024, but the rollout is phased. As of mid-2026, NHS prescribing has opened to people with a BMI of 40 or above plus four or more qualifying conditions, with the next cohort (BMI 35–39.9 plus four conditions) activated in June 2026. Many people who would benefit clinically do not yet meet those thresholds, or do not want to wait.

A regulated private online pharmacy offers a legal, clinically supervised route. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not an automated decision. If approved, your treatment is dispatched the same day for free next-working-day delivery with DPD; the pen arrives in plain unbranded packaging, tracked to your door. You can verify our pharmacy on the GPhC register (registration 9012878).

If you are considering treatment based on the trial evidence above, the right starting point is a clinical assessment. Read more about what shapes outcomes in our evidence summary for Mounjaro, or explore patient experiences through accounts from people who have used it. When you are ready, speak to our prescribers through a free consultation on our treatment page.